Sean Maduck - 25 Aug 2026 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Reporting relationship: Officer
Issuer ticker: CORT
Reported as of: 25 Aug 2026
Net transaction value: -$3,887,320
SEC form: 4
Accepted by SEC: 27 Aug 2026, 16:30:04 UTC
Prior SEC filing: 18 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck

Key filing fact

Sean Maduck filed Form 4 for CORCEPT THERAPEUTICS INC (CORT) on 27 Aug 2026.

Key facts

This page summarizes Sean Maduck's Form 4 filing for CORCEPT THERAPEUTICS INC (CORT).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 Aug 2026, 16:30.

Change

Previous filing in this sequence was filed on 18 Aug 2026.
Current net transaction value: -$3,887,320.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001698310 Primary reporting owner

Maduck Sean

Relationship: Officer
Address: C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Signature: /s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck
Signature date: 27 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CORT transaction

Common Stock

Options Exercise

Transaction value
Shares: +30,955
Change %: +317%
Price: $11.35^*
Shares after: 40,710
Date: 25 Aug 2026
Ownership: Direct
Footnotes: F1

CORT transaction

Common Stock

Sale

Transaction value: $3,147,355
Shares: -25,085
Change %: -62%
Price: $125.47
Shares after: 15,625
Date: 25 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3

CORT transaction

Common Stock

Sale

Transaction value: $739,965
Shares: -5,870
Change %: -38%
Price: $126.06
Shares after: 9,755
Date: 25 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F4

CORT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,147
Date: 25 Aug 2026
Ownership: See Footnote
Footnotes: F5

CORT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 20,570
Date: 25 Aug 2026
Ownership: See Footnote
Footnotes: F6

CORT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 40,000
Date: 25 Aug 2026
Ownership: See Footnote
Footnotes: F7

CORT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 34,000
Date: 25 Aug 2026
Ownership: See Footnote
Footnotes: F8

CORT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 10,000
Date: 25 Aug 2026
Ownership: See Footnote
Footnotes: F9

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CORT transaction Derivative

Stock option (right to buy)

Options Exercise

Transaction value
Shares: -30,955
Change %: -15%
Price: $0.000000^*
Shares after: 169,045
Date: 25 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,955
Exercise price: $11.35
Footnotes: F10

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 10 footnotes

Footnote F1

Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Footnote F2

This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.

Footnote F3

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $125.00 to $125.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Footnote F4

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $126.00 to $126.23 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Footnote F5

Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.

Footnote F6

Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.

Footnote F7

Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

Footnote F8

Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

Footnote F9

Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Footnote F10

Fully exercisable.

SEC remarks

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .